Long-term oxygen therapy (LTOT) is the only intervention outside smoking cessation that demonstrably reduces mortality in severe COPD. The original NOTT and MRC trials in the early 1980s established a 1.7-fold survival improvement in patients with PaO2 ≤ 55 mmHg who used oxygen for ≥15 hours a day. Forty years on, the prescription criteria have barely shifted. What has shifted is the equipment, the regulatory frame in India, and the patient pathway — and that is where most Indian buyers run into trouble.
This guide threads GOLD staging into the LTOT decision, lays out the PaO2 and SpO2 thresholds, and addresses the Indian-market specifics that tend to break the prescription chain: CGHS/ECHS coverage, dealer-channel depth, voltage stress, and why pulmonologist-led titration matters more than the patient’s instinct or the dealer’s pitch.
GOLD staging: what it actually classifies
GOLD (Global Initiative for Chronic Obstructive Lung Disease) classifies COPD across two axes that are routinely conflated in lay discussions.
Spirometric severity (GOLD 1-4) uses post-bronchodilator FEV1 as a percentage of predicted, in patients with confirmed FEV1/FVC < 0.70:
- GOLD 1 (mild): FEV1 ≥ 80% predicted
- GOLD 2 (moderate): FEV1 50-79% predicted
- GOLD 3 (severe): FEV1 30-49% predicted
- GOLD 4 (very severe): FEV1 < 30% predicted
Symptom and exacerbation grouping (A, B, E) in the current GOLD framework combines symptom burden (mMRC ≥ 2 or CAT ≥ 10) with exacerbation history (≥ 2 moderate exacerbations or ≥ 1 hospitalisation in the past year) (GOLD Report).
Group A is low-symptom, low-risk. Group B is high-symptom, low-risk. Group E is anyone with significant exacerbation history regardless of symptom load. Pharmacological escalation pathways differ across A/B/E.
LTOT decisions sit largely outside this taxonomy. They are driven not by FEV1 percentile or by ABE group but by the gas-exchange measurement at the time of assessment. A GOLD 2 patient with significant resting hypoxaemia qualifies for LTOT; a GOLD 4 patient whose PaO2 stays above threshold does not. The Indian habit of equating “very severe COPD” with “needs concentrator” is wrong. Spirometry indexes airflow obstruction; LTOT indication indexes oxygenation.
The LTOT criteria
The threshold criteria for continuous LTOT in stable COPD have been essentially constant for four decades (GOLD Report).
Primary criterion (any one):
- PaO2 ≤ 55 mmHg, or
- SpO2 ≤ 88% at rest, breathing room air, awake.
Secondary criterion (PaO2 56-59 mmHg or SpO2 ≤ 89% with one of):
- Cor pulmonale (echocardiographic right-heart strain)
- Erythrocytosis with haematocrit > 55%
- Pulmonary hypertension on echo
The measurement must be made when the patient is clinically stable — at least 30 days from the last exacerbation, on optimal pharmacotherapy, and not during a respiratory infection. A PaO2 measured at the back end of an exacerbation often improves by 5-10 mmHg over the following month and may take the patient out of the LTOT band entirely. Prescribing on a hospital-discharge ABG without re-checking at 30 days is a common Indian-market overprescription pattern.
The dosing rule is similarly simple and similarly unforgiving: oxygen must be used for at least 15 hours per day, including overnight, to capture the mortality benefit. Patients who use the concentrator only when they feel breathless capture little of the survival signal. The therapy works because it is sustained, not because it intermittently corrects symptoms.
When 5 LPM is enough vs 10 LPM is needed
A formal titration produces a flow rate that holds the patient at the target SpO2 (88-92% in this CO2-retention-risk population) at rest, on exertion, and overnight. The flow rate maps to equipment class:
5 LPM stationary concentrator covers the large majority of stable LTOT patients. Resting prescription is typically 1-3 LPM; exertion may need 3-5 LPM; overnight is usually 0.5-1 LPM higher than daytime. A 5 LPM unit delivers rated 90-95% O2 purity up to its labelled flow; above that, purity drops as the sieve cycle stops keeping up.
10 LPM stationary concentrator is indicated when:
- Resting requirement consistently crosses 4-5 LPM
- Exertion or post-exacerbation need pushes past 5 LPM
- Two patients in the same household share the concentrator via Y-splitter (purity at 2.5 LPM x 2 from a 5 LPM unit drops to 80-85% which is no longer therapeutic)
- The patient is on bilevel NIV with supplemental oxygen entrained at the circuit and the bias flow eats into the delivered FiO2
Adding a portable for ambulation is a quality-of-life intervention more than a clinical one. A patient on stationary 3 LPM at home who walks to a temple, attends a hospital follow-up, or visits family across the city without supplemental oxygen will desaturate during the trip and may decompensate. Pulse-dose portables (typically 1-5 setting) cover this if the resting equivalent need is in the 1-2 LPM range; continuous-flow portables cover higher needs but at battery-life cost.
The configuration the Indian market most often gets wrong: continuous LTOT prescribed without a portable, and the patient stops leaving the house. This is undertreatment of disability, and at six months produces measurable deconditioning.
Exercise oxygen vs continuous oxygen
A small subgroup has normal resting saturation but exertion-induced desaturation. Strict LTOT criteria are not met because the resting PaO2 is above 55 mmHg, but the patient drops below 88% during a 6-minute walk. Evidence for mortality benefit in this group is weaker than for resting hypoxaemia. Symptomatic and pulmonary-rehab benefit is more solid.
The decision typically goes one of two ways. Either the patient is enrolled in pulmonary rehab and uses supplemental oxygen during exercise sessions only, or a portable concentrator is prescribed for use during ADLs that consistently desaturate the patient. Continuous LTOT is not justified.
The Indian-market specifics
CGHS, ECHS, ESIC, and private insurance. Concentrator coverage under CGHS is procedural: the prescribing pulmonologist (CGHS empanelled or referred) writes the prescription specifying flow rate and class, the patient submits to the wellness centre, an empanelled durable-medical-equipment vendor delivers the unit, and reimbursement runs through the standard medical-equipment claim path. ECHS follows broadly similar logic for ex-servicemen. ESIC coverage is patchy and state-dependent. Private health insurance in India typically does not cover LTOT capital cost — the concentrator is treated as durable medical equipment outside hospitalisation cover. Patients commonly buy out-of-pocket or rent monthly. Verify coverage in writing before commitment.
Tier-1 vs Tier-2/3 dealer-channel depth. Mumbai, Bengaluru, Delhi, Hyderabad and Chennai have deep concentrator dealer networks: Oxymed, Philips, BPL and several Chinese OEM importers all carry inventory, service vans, and biomed support. Tier-2 cities (Indore, Vizag, Coimbatore, Lucknow, Patna) typically have 2-3 active dealers per city, with Inogen and ResMed effectively absent. Tier-3 and rural dealers are usually generalists who carry one or two brands and depend on factory service for anything beyond a filter swap. The decision implication: in Tier-3, prefer brands with national service contracts (Philips, Oxymed) over imports without local depth, even if the import has a better spec sheet.
Voltage stress. A 5 LPM concentrator’s compressor is the most failure-prone component. Indian Tier-2 mains routinely swing 160-260V; over months, this kills compressors. A 1.5-2 kVA servo stabiliser added at install costs ₹4,000-₹7,000 and roughly doubles compressor life. Pure-sine inverters with 4-6 hour battery backup add another ₹15,000-₹25,000 and matter for any continuous-LTOT patient where load-shedding is a regular event. The dealer often does not raise this question; the buyer should.
Pulmonologist-led titration vs self-prescription. The most common Indian failure mode is a patient with mid-stage COPD who buys a concentrator on the basis of a fingertip oximeter and the dealer’s recommendation, sets it at 2 LPM “because that’s what most people use,” and then sits at 92-94% saturation indefinitely. Two problems: the patient may not actually meet LTOT criteria (so is taking on capital and electricity cost without a survival benefit), or the patient does meet criteria but is undertreated overnight and on exertion (so is paying for the concentrator without getting the survival benefit). Both errors are avoided by an ABG, a formal titration, and a written prescription (Indian Chest Society).
Equipment selection within the prescription class
Once the prescription is settled (5 LPM or 10 LPM stationary, with or without a portable), brand selection is a separate exercise. The decision criteria are noise, energy efficiency at a 5-year horizon, sieve life, dealer service depth at the patient’s city, and HHZ rubric scoring on the published spec.
In the 5 LPM stationary segment, the established options are the Philips EverFlo Q, Oxymed Mini, BPL Oxy 5N, and Home Medix HM-KV against several Chinese OEM units (Owgels, Yuwell, Longfian). In the 10 LPM segment, the field narrows: Oxymed Mini 10, BPL Oxy 10N, Home Medix HM-KX, and a thinner Chinese OEM bench.
Service depth at the patient’s location should override spec-sheet differences of 1-2 dBA noise or 50W energy draw. A concentrator that breaks down and waits 11 days for a service technician is therapeutically zero for those 11 days, which matters more than any 2026 spec advantage.
The takeaway
LTOT is a survival therapy with a four-decade evidence base, but the survival benefit is conditional on the prescription being correct and the dose (≥15 hours/day) being delivered. GOLD staging frames the disease; the LTOT decision is driven by gas-exchange thresholds, formal titration, and pulmonologist-led prescription — not by the patient’s spirometry stage and not by the dealer’s intuition. Get the prescription right first, then size the equipment.
This guide is editorial opinion and general information. It is not medical advice. Consult your physician for therapy decisions, and verify all specifications with the manufacturer before purchase.